Byondis

Focus: Byondis is a Netherlands-based biotechnology company specializing in antibody-drug conjugates (ADCs) and monoclonal antibodies, with a pipeline focused on oncology and neurology indications. As a public-stage biotech, the company operates at the interface of early development and clinical advancement.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Byondis

AI assessmentNot Hiring

No open roles listed right now. Follow Byondis to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SYD1875

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT04202705A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875

Phase 1

Help build intelligence for Byondis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge ADC and monoclonal antibody platform technology with multiple Phase 1-3 programs across solid tumors, breast cancer, and hematologic malignancies
Opportunity to contribute to SYD985 Phase 3 program in metastatic breast cancer, the company's most advanced asset with near-term regulatory catalyst potential
Public company status provides equity upside potential and established governance structure versus earlier-stage private biotech

Watch Out For

Currently zero open positions listed (activeJobCount: 0), suggesting limited immediate hiring or potential restructuring phase
Limited publicly available financial data (revenue, R&D spend, cash position unknown) makes career stability assessment difficult
Heavy reliance on Phase 1 programs (9 of 11 trials) indicates prolonged development timeline and execution risk before value inflection

Generated by Claude from Byondis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SYD985

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT02277717First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

Phase 1

BYON4413

Relapsed / Refractory AML

PHASE_1

Clinical Trials (1)

NCT06359002Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Phase 1

Vic-trastuzumab duocarmazine

HER2-positive Breast Cancer

PHASE_1

Clinical Trials (1)

NCT04602117ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Phase 1

BYON3521

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT05323045A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Phase 1

BYON4228 + Rituximab

Lymphoma

PHASE_1

Clinical Trials (1)

NCT05737628First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Phase 1

BYON4228 + Pembrolizumab

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT06932952A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors

Phase 1

SYD985 + Niraparib

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT04235101Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

Phase 1

BYON5667 & SYD985

Metastatic Breast Cancer

PHASE_1_2

Clinical Trials (1)

NCT04983238Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985

Phase 1/2

SYD985

Endometrial Cancer

PHASE_2

Clinical Trials (1)

NCT04205630SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Phase 2

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Brea

Metastatic Breast Cancer

PHASE_3

Clinical Trials (1)

NCT03262935SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 11 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

10 pipeline

Marketed

Pipeline